drugset / Trial / NCT03575520
Safety and Efficacy of Pegteograstim in Korean Breast Cancer Patients
NaSingle-groupOpen-labelTreatment
Summary
This is a prospective, single arm study, which is examining doxorubicin and cyclophosphamide (AC) once every 2 weeks with pegteograstim support in Korean early breast cancer.
Timeline
- Start
- 2016-06-07
- Primary completion
- 2017-02-15
- Completion
- 2017-03-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pegfilgrastim | Protein / enzyme biologic | 6 mg | Subcutaneous |
| Background | Cyclophosphamide | Other / unclassified | 600 mg/m2 | Intravenous |
| Background | Doxorubicin | Other / unclassified | 60 mg/m2 | Intravenous |